Notify me when Growth Equity Opportunities 18 VGE, LLC files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals, Inc. | Common Stock, par value $0.001 per share | 6.2% | $17,496,802 | +$9,734,867 | 5,057,610 | +125% | Growth Equity Opportunities 18 VGE, LLC | 27 Oct 2025 |
| CELC | Celcuity Inc. | Common Stock, $0.001 par value per share | 4.9% | $238,224,023 | -$65,143,750 | 2,285,561 | -21% | Growth Equity Opportunities 18 VGE, LLC | 05 Mar 2026 |
| GOSS | Gossamer Bio, Inc. | Common Stock, $0.0001 par value per share | 1.7% | $10,366,092 | 4,065,134 | Growth Equity Opportunities 18 VGE, LLC | 23 Feb 2026 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|